GlossaryPod – Structure, Process, & Outcome
ruth brice2021-07-09T08:44:05+00:00
9
07, 2021
28
06, 2019
Paper of the Week 28th June 2019: The Precision of Evidence Needed to Practice “Precision Medicine”
ruth brice2019-06-28T12:29:34+00:00This weeks Paper of the Week is brought to you by: Professor Sir Muir Gray Author’s Conclusion “In July 2018, the Journal published the results of TAILORx (Trial Assigning Individualized Option for Treatment).1 This randomized trial conducted by Sparano et al. showed the noninferiority of endocrine therapy to chemoendocrine therapy with respect to invasive disease–free survival among women with hormone-receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative, axillary node–negative breast cancer who had a recurrence score (based on a 21-gene assay) of 11 to 25 (scores range from 0 to 100, with higher scores predicting a higher risk of distant recurrence)… Less than a year later, we are publishing additional results from the same data [...]
17
05, 2019
Paper of the Week 17th May 2019:Measuring What Matters in Diabetes
ruth brice2019-05-17T11:48:31+00:00Full reference: MA. Published online April 15, 2019. doi:10.1001/jama.2019.4310 This weeks blog is brought to you by: Professor Sir Muir Gray, Founding Director Authors conclusion “The rationale for using HbA1c level as a surrogate for diabetes outcomes is predicated on the assumption of its direct correlation with outcomes that patients ultimately value, including clinical microvascular disease (eg, ESKD and need for dialysis, blindness, neuropathic pain, amputation), macrovascular disease (eg, myocardial infarction, stroke, painful neuropathy), quality of life, and death. Yet, the strength of this relationship has been called into question. Meta-analyses revealed a null association between intensive glycemic control and these patient-important outcomes, with the sole exception of a 10% to 15% relative risk reduction of nonfatal myocardial [...]
1
03, 2019
Paper of the week 27.02.19: Has the NHS Long Term Plan forgotten we are all going to die?
ruth brice2019-03-01T11:14:40+00:00Reference: Has the Long Term Plan forgotten we are all going to die? (Bleakley T., Smith R., Taylor R) This week’s paper of the week is brought to you by Professor Sir Muir Gray, 3V’s Founding Director. Bottom line, chosen by Muir from the paper "One certainty is that there will be a lot of dying in the next 10 years as the baby boomers become the dying boomers... Increasingly, people endure slow deaths of frailty, often with dementia in the final years. Increased life expectancy is generally regarded as a cause for celebration, but many people fear dependency and dementia more than they fear death... Between a quarter and a third of health-care expenditure is for care [...]
7
11, 2018
Paper of the week 07.11.18: Progress in clinical research in surgery and IDEAL
ruth brice2018-11-07T15:21:45+00:00Reference: Progress in clinical research in surgery and IDEAL. Peter McCulloch et al (2018) Lancet 2018; 392: 88–94 This weeks paper of the week is brought to you by Professor Sir Muir Gray, 3V Executive Director. Bottom line “The Idea, Development, Exploration, Assessment, and Long-term Follow-up (IDEAL) Framework and Recommendations specify desirable qualities for surgical studies, and outline an integrated evaluation pathway for surgery, and similar complex interventions. We used the IDEAL Recommendations to assess methodological progress in surgical research over time, assessed the uptake and influence of IDEAL, and identified the challenges to further methodological progress. Comparing studies from the periods 2000–04 and 2010–14, we noted apparent improvement in the use of standard outcome measures, adoption of [...]